Cybersecurity firm Senetas (ASX: SEN) is making waves in the Middle East, having secured a $2 million order through global distributor Thales, for their Ultra-High speed 100Gbps Ethernet encryptors. The CN9000 series encryptors will be deployed to secure the data in transit of a Middle Eastern government agency, enabling protection of their data network without
Read More
To counter rising concerns around the environmental impact of disposable face masks being used to restrict the spread of COVID-19, Australian Primary Hemp (ASX: APH) has launched a new hemp-based face mask which provides 99.9% microbial reduction. The face masks are reusable, biodegradable and sustainably-sourced with the Company to commence supplying the masks to Australian
Read More
New Zealanders keen to utilise buy-now-pay-later services for bulky purchases will soon be able to access interest-free payment terms through humm, with FlexiGroup (ASX: FXL) set to launch their BNPL service across the Tasman. With other BNPL services offering payment plans for purchases up to $1,000, Flexigroup has carved out it’s unique role in the
Read More
Pharmaceuticals company AusCann (ASX: AC8) is set to progress to the next stage of clinical trials having successfully completed their first round on Neuvis, their cannabinoid-based capsule developed to treat nerve pain – an area of medicine that is inadequately met. Estimated to affect 7-10% of Australians, nerve pain is caused by damage to the
Read More
Tech and eCommerce company Crowd Media (ASX: CM8) is forging ahead with their vision of conversational commerce by securing equity in a vital tech partner that develops visual projections which, when coupled with Crowd’s artificial intelligence, can deliver the ‘Holy Grail’ of influencer marketing. The $365k investment in Forever Holdings will give Crowd Media 8%
Read More
US markets were stronger in the month, with the Dow Jones up +7.57% and S&P500 up +7.01%, on back of vaccine progress with Russia giving regulatory approval for the world’s first Covid-19 vaccine for use with mass inoculation to start soon and Pfizer Inc. announcing its Covid-19 vaccine is on track to seeking regulatory review
Read More